NCT02015065View on ClinicalTrials.gov

Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 14, 2013

Primary Completion Date

May 4, 2016

Study Completion Date

December 10, 2019

Conditions
GIST
Interventions
DRUG

Vandetanib

Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02015065 - Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | Biotech Hunter | Biotech Hunter